Cipla announced its financial results for the second quarter of FY27, reporting a revenue of ₹7,404 crore, marking a 4% sequential growth (Q-o-Q). The company highlighted strong performance in its One India business, which recorded its highest-ever quarterly revenue, and resilience in its global portfolio. Key strategic developments include partnerships and approvals in the biosimilar and respiratory segments, alongside ongoing R&D investments. Management expressed confidence in sustaining momentum through pipeline advancements and disciplined commercial execution.
Cipla Reports Strong Q2 FY27 Earnings
Cipla Limited has disclosed its financial performance for the second quarter of the financial year 2027 (Q2 FY27), ending October 27, 2026. The company announced a robust quarterly revenue of INR 7,404 crores, reflecting a healthy 4% sequential growth (Q-o-Q). This achievement is attributed to broad-based performance across its key business segments.
Key Business Highlights
The One India business segment delivered an impressive 12% Year-on-Year growth, continuing its track record of consistent double-digit growth. This performance was driven by strong execution across core therapies and the resilience of its franchise within the Indian Pharmaceutical Market (IPM). The branded prescription business also saw significant growth, with a 15% increase, primarily led by the chronic portfolio, as per IQVIA data for Year-To-Date September 2026.
Key chronic therapies demonstrated notable growth: respiratory increased by 11%, antidiabetes by 50% (including GLP), urology by 11%, and dermatology by 16%. This expansion is underpinned by strong brand equity, robust volume growth, and effective field execution.
Global Portfolio and Strategic Initiatives
Globally, Cipla’s portfolio showed resilience amidst a dynamic operating environment. The company continues to invest in its pipeline, achieving significant milestones such as the first DPI approval of generic Advair in the U.S. and a partnership with Qilu for Pembrolizumab in North America. Clinical development for another respiratory biosimilar asset has also commenced.
The trade generic business experienced strong double-digit Q-o-Q growth, supported by new product launches. The Consumer Health business also maintained its upward trajectory with key brands like Nicotex, Omnigel, and Cipladine solidifying their market positions.
North America Performance
In North America, Cipla generated a quarterly revenue of $172 million in Q2 FY27, representing an improvement of $10 million from the previous quarter. The company remains the number one player in the overall U.S. Albuterol MDI market, holding a 22% market share as per IQVIA data.
Financial Performance Overview
Dinesh Jain, Global CFO, presented the financial highlights. The EBITDA margin, excluding other income, stood at 18.7% for the quarter, a sequential improvement of 200 basis points. Gross margin after material costs was 64.4%, up 7% Q-o-Q, attributed to an improved product mix. Total expenses for the quarter were INR 3,382 crores, a 4% increase Q-o-Q, reflecting planned investments in product launches and manufacturing readiness. R&D investments amounted to INR 423 crores, representing 5.7% of revenue.
Profit after tax for the quarter was INR 878 crores, an 11.9% margin on sales, with a sequential improvement of 77 basis points. The company maintained a strong net cash position, with a balance of INR 9,823 crores as of September 30, 2026.
Future Outlook
Looking ahead, Cipla’s priorities include sustained growth in the Indian market, strengthening its presence in chronic therapies, and driving top-line growth in emerging markets. The company remains focused on its U.S. business, aiming for a $1 billion annualized revenue run rate by the fiscal year-end.
Source: BSE
